23IN - Anaplastic glioma: Will molecular profiling override histology?

Date 29 September 2012
Event ESMO Congress 2012
Session Molecular neuro-oncology: New avenues in diagnosis and treatment
Topics Central Nervous System Malignancies
Pathology/Molecular Biology
Presenter Martin van den Bent
Authors M.J. van den Bent
  • Neuro-oncology, ErasmusMC - Daniel den Hoed Cancer Center, 3075EA - Rotterdam/NL

Abstract

The histopathological diagnosis of anaplastic glioma is complicated by a disturbing interobserver variation. Several molecular assays are now of demonstrated value in anaplastic glioma. Recent randomized trials have shown that 1p/19q co-deletion is not only prognostic, but also predictive for improved outcome to RT with adjuvant PCV. Also, testing for IDH mutations is helpful for the in diagnosis of grade II and grade III, and has significant prognostic implications. MGMT promoter methylation in anaplastic gliomas seems to be the result of alter cell metabolism induced by IDH mutations which leads to the CpG island hypermethylation. Therefore, in anaplastic glioma MGMT promoter methylation appears to reflect IDH status.

Conclusion

over the past two years, the role of molecular testing has greatly increased in the management of anaplastic gliomas.

Disclosure

The author has declared no conflicts of interest.